Overexpression of Folate receptor–α (FRα) protein on cell surfaces has been identified to be a common marker in many ovarian cancers, which is one of the most common cancers among women. Advances in immuno-oncology have featured this target in several novel therapeutics looking to combat ovarian cancer. 

Key aspects of FRα:

Protein: FRα is a cell surface protein primarily involved in folate binding.

Expression: Low in normal tissues and highly expressed in various tumor tissues

Indications: Non-small cell lung cancer, triple-negative breast cancer, mesothelioma, and epithelial ovarian cancer.

Exciting advancements in FRα-targeting drugs include: 

Approved FRα ADC: Mirvetuximab soravtansine (Elahere)

FRα ADCs in clinical trials: STRO-002(Sutro Biopharma); MORAb-202(Eisai); BAT8006(Bio-Thera)

A new way to reproduce Tau and α-synuclein propagation in the brain?

Explore the modeling potential of Pre-formed Fibrils (PFFs)

The formation of cytotoxic species of tau and α-synuclein leading to formation of insoluble filaments

However, a factor in the stagnation of research into developing more effective therapies against AD and PD is largely due to the inability of animal models to simulate human patient diseases; in other words, the lack of animal models that can reflect the progression of the disease and the efficacy of drugs. 

We are available at

Awards & Certifications